Last reviewed · How we verify
anti-tumour necrosis factor α antibodies
anti-tumour necrosis factor α antibodies is a TNF-α inhibitor (monoclonal antibody) Small molecule drug developed by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). It is currently in Phase 3 development for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Ankylosing spondylitis.
Anti-TNF-α antibodies bind to and neutralize tumor necrosis factor alpha, a key pro-inflammatory cytokine, thereby reducing inflammation and immune-mediated tissue damage.
Anti-TNF-α antibodies bind to and neutralize tumor necrosis factor alpha, a key pro-inflammatory cytokine, thereby reducing inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Ankylosing spondylitis.
At a glance
| Generic name | anti-tumour necrosis factor α antibodies |
|---|---|
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | TNF-α inhibitor (monoclonal antibody) |
| Target | TNF-α (Tumor Necrosis Factor Alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TNF-α is a central mediator of inflammation and plays a critical role in various autoimmune and inflammatory diseases. By blocking TNF-α signaling through direct antibody binding, these agents suppress the inflammatory cascade and reduce pathological immune activation. This mechanism has proven effective in conditions driven by excessive TNF-α production, including rheumatoid arthritis, inflammatory bowel disease, and other autoimmune disorders.
Approved indications
- Rheumatoid arthritis
- Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Ankylosing spondylitis
- Psoriasis and psoriatic arthritis
Common side effects
- Increased infection risk (including tuberculosis and opportunistic infections)
- Injection site reactions
- Headache
- Upper respiratory tract infections
- Demyelinating disease (rare)
Key clinical trials
- Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (PHASE2)
- Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases (NA)
- Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation (NA)
- Surgical Closure vs Anti-TNF in the Treatment of Perianal Fistulas in Crohn's Disease (PISA-II): a Comprehensive Cohort Design (PHASE3)
- Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients (NA)
- Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients (PHASE4)
- Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis (PHASE3)
- Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-tumour necrosis factor α antibodies CI brief — competitive landscape report
- anti-tumour necrosis factor α antibodies updates RSS · CI watch RSS
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) portfolio CI
Frequently asked questions about anti-tumour necrosis factor α antibodies
What is anti-tumour necrosis factor α antibodies?
How does anti-tumour necrosis factor α antibodies work?
What is anti-tumour necrosis factor α antibodies used for?
Who makes anti-tumour necrosis factor α antibodies?
What drug class is anti-tumour necrosis factor α antibodies in?
What development phase is anti-tumour necrosis factor α antibodies in?
What are the side effects of anti-tumour necrosis factor α antibodies?
What does anti-tumour necrosis factor α antibodies target?
Related
- Drug class: All TNF-α inhibitor (monoclonal antibody) drugs
- Target: All drugs targeting TNF-α (Tumor Necrosis Factor Alpha)
- Manufacturer: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Inflammatory bowel disease (Crohn's disease and ulcerative colitis)
- Indication: Drugs for Ankylosing spondylitis
- Compare: anti-tumour necrosis factor α antibodies vs similar drugs
- Pricing: anti-tumour necrosis factor α antibodies cost, discount & access